Effect of the common -866GA polymorphism of the uncoupling protein 2 gene on weight loss and body composition under sibutramine therapy in an obese taiwanese population

Tun Jen Hsiao, Lawrence Shih Hsin Wu, Yuchi Hwang, Shih Yi Huang, Eugene Lin

研究成果: 雜誌貢獻文章

8 引文 (Scopus)

摘要

Background: Sibutramine, a serotonin and norepinephrine reuptake inhibitor, is used as an anti-obesity drug. Several pharmacogenetic studies have shown correlations between sibutramine effects and genetic variants, such as the 825C/T (rs5443) single nucleotide polymorphism (SNP) in the guanine nucleotide binding protein beta polypeptide 3 (GNB3) gene. Objective: In this study, our goal was to investigate whether a common SNP, -866G/A (rs659366), in the uncoupling protein 2 (UCP2) gene could influence weight reduction and body composition under sibutramine therapy in an obese Taiwanese population. Methods: The study included 131 obese patients, 44 in the placebo group and 87 in the sibutramine group. We assessed the measures of weight loss and body fat reduction at the end of a 12-week treatment period by analysis of covariance (ANCOVA) models using gender, baseline weight, and body fat percentage at baseline as covariates. Results and Conclusion: By comparing the placebo and sibutramine groups withANCOVA, our data showed a strong effect of sibutramine on weight loss in the combined UCP2 -866 AA+GA genotype groups (p <0.001). Similarly, a strong effect of sibutramine on body fat percentage loss was found for individuals with the AA or GA genotypes (p <0.001). In contrast, sibutramine had no significant effect on weight loss (p = 0.063) or body fat percentage loss (p = 0.194) for individuals with the wild-typeGGgenotype, compared with the placebo group of the same genotype. Moreover, a potential gene-gene interaction between UCP2 and GNB3 was identified by multiple linear regression models for the weight loss (p <0.001) and for the percent fat loss (p = 0.031) in response to sibutramine. The results suggest that the UCP2 gene may contribute to weight loss and fat change in response to sibutramine therapy in obese Taiwanese patients.

原文英語
頁(從 - 到)101-106
頁數6
期刊Molecular Diagnosis and Therapy
14
發行號2
DOIs
出版狀態已發佈 - 2010

指紋

sibutramine
Body Composition
Weight Loss
Population
Genes
Adipose Tissue
Therapeutics
Genotype
Placebos
Single Nucleotide Polymorphism
Linear Models
Fats
Uncoupling Protein 2
Anti-Obesity Agents

ASJC Scopus subject areas

  • Genetics
  • Molecular Medicine
  • Medicine(all)
  • Pharmacology

引用此文

Effect of the common -866GA polymorphism of the uncoupling protein 2 gene on weight loss and body composition under sibutramine therapy in an obese taiwanese population. / Hsiao, Tun Jen; Wu, Lawrence Shih Hsin; Hwang, Yuchi; Huang, Shih Yi; Lin, Eugene.

於: Molecular Diagnosis and Therapy, 卷 14, 編號 2, 2010, p. 101-106.

研究成果: 雜誌貢獻文章

@article{d30f21fcbad24f8fbbfaa75f1cece22a,
title = "Effect of the common -866GA polymorphism of the uncoupling protein 2 gene on weight loss and body composition under sibutramine therapy in an obese taiwanese population",
abstract = "Background: Sibutramine, a serotonin and norepinephrine reuptake inhibitor, is used as an anti-obesity drug. Several pharmacogenetic studies have shown correlations between sibutramine effects and genetic variants, such as the 825C/T (rs5443) single nucleotide polymorphism (SNP) in the guanine nucleotide binding protein beta polypeptide 3 (GNB3) gene. Objective: In this study, our goal was to investigate whether a common SNP, -866G/A (rs659366), in the uncoupling protein 2 (UCP2) gene could influence weight reduction and body composition under sibutramine therapy in an obese Taiwanese population. Methods: The study included 131 obese patients, 44 in the placebo group and 87 in the sibutramine group. We assessed the measures of weight loss and body fat reduction at the end of a 12-week treatment period by analysis of covariance (ANCOVA) models using gender, baseline weight, and body fat percentage at baseline as covariates. Results and Conclusion: By comparing the placebo and sibutramine groups withANCOVA, our data showed a strong effect of sibutramine on weight loss in the combined UCP2 -866 AA+GA genotype groups (p <0.001). Similarly, a strong effect of sibutramine on body fat percentage loss was found for individuals with the AA or GA genotypes (p <0.001). In contrast, sibutramine had no significant effect on weight loss (p = 0.063) or body fat percentage loss (p = 0.194) for individuals with the wild-typeGGgenotype, compared with the placebo group of the same genotype. Moreover, a potential gene-gene interaction between UCP2 and GNB3 was identified by multiple linear regression models for the weight loss (p <0.001) and for the percent fat loss (p = 0.031) in response to sibutramine. The results suggest that the UCP2 gene may contribute to weight loss and fat change in response to sibutramine therapy in obese Taiwanese patients.",
keywords = "Clinical-genetics, General, Genetic-polymorphism, Genotyping, Obesity, Pharmacogenetics, Sibutramine, Weight-loss",
author = "Hsiao, {Tun Jen} and Wu, {Lawrence Shih Hsin} and Yuchi Hwang and Huang, {Shih Yi} and Eugene Lin",
year = "2010",
doi = "10.2165/11532940-000000000-00000",
language = "English",
volume = "14",
pages = "101--106",
journal = "Molecular Diagnosis and Therapy",
issn = "1177-1062",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - Effect of the common -866GA polymorphism of the uncoupling protein 2 gene on weight loss and body composition under sibutramine therapy in an obese taiwanese population

AU - Hsiao, Tun Jen

AU - Wu, Lawrence Shih Hsin

AU - Hwang, Yuchi

AU - Huang, Shih Yi

AU - Lin, Eugene

PY - 2010

Y1 - 2010

N2 - Background: Sibutramine, a serotonin and norepinephrine reuptake inhibitor, is used as an anti-obesity drug. Several pharmacogenetic studies have shown correlations between sibutramine effects and genetic variants, such as the 825C/T (rs5443) single nucleotide polymorphism (SNP) in the guanine nucleotide binding protein beta polypeptide 3 (GNB3) gene. Objective: In this study, our goal was to investigate whether a common SNP, -866G/A (rs659366), in the uncoupling protein 2 (UCP2) gene could influence weight reduction and body composition under sibutramine therapy in an obese Taiwanese population. Methods: The study included 131 obese patients, 44 in the placebo group and 87 in the sibutramine group. We assessed the measures of weight loss and body fat reduction at the end of a 12-week treatment period by analysis of covariance (ANCOVA) models using gender, baseline weight, and body fat percentage at baseline as covariates. Results and Conclusion: By comparing the placebo and sibutramine groups withANCOVA, our data showed a strong effect of sibutramine on weight loss in the combined UCP2 -866 AA+GA genotype groups (p <0.001). Similarly, a strong effect of sibutramine on body fat percentage loss was found for individuals with the AA or GA genotypes (p <0.001). In contrast, sibutramine had no significant effect on weight loss (p = 0.063) or body fat percentage loss (p = 0.194) for individuals with the wild-typeGGgenotype, compared with the placebo group of the same genotype. Moreover, a potential gene-gene interaction between UCP2 and GNB3 was identified by multiple linear regression models for the weight loss (p <0.001) and for the percent fat loss (p = 0.031) in response to sibutramine. The results suggest that the UCP2 gene may contribute to weight loss and fat change in response to sibutramine therapy in obese Taiwanese patients.

AB - Background: Sibutramine, a serotonin and norepinephrine reuptake inhibitor, is used as an anti-obesity drug. Several pharmacogenetic studies have shown correlations between sibutramine effects and genetic variants, such as the 825C/T (rs5443) single nucleotide polymorphism (SNP) in the guanine nucleotide binding protein beta polypeptide 3 (GNB3) gene. Objective: In this study, our goal was to investigate whether a common SNP, -866G/A (rs659366), in the uncoupling protein 2 (UCP2) gene could influence weight reduction and body composition under sibutramine therapy in an obese Taiwanese population. Methods: The study included 131 obese patients, 44 in the placebo group and 87 in the sibutramine group. We assessed the measures of weight loss and body fat reduction at the end of a 12-week treatment period by analysis of covariance (ANCOVA) models using gender, baseline weight, and body fat percentage at baseline as covariates. Results and Conclusion: By comparing the placebo and sibutramine groups withANCOVA, our data showed a strong effect of sibutramine on weight loss in the combined UCP2 -866 AA+GA genotype groups (p <0.001). Similarly, a strong effect of sibutramine on body fat percentage loss was found for individuals with the AA or GA genotypes (p <0.001). In contrast, sibutramine had no significant effect on weight loss (p = 0.063) or body fat percentage loss (p = 0.194) for individuals with the wild-typeGGgenotype, compared with the placebo group of the same genotype. Moreover, a potential gene-gene interaction between UCP2 and GNB3 was identified by multiple linear regression models for the weight loss (p <0.001) and for the percent fat loss (p = 0.031) in response to sibutramine. The results suggest that the UCP2 gene may contribute to weight loss and fat change in response to sibutramine therapy in obese Taiwanese patients.

KW - Clinical-genetics

KW - General

KW - Genetic-polymorphism

KW - Genotyping

KW - Obesity

KW - Pharmacogenetics

KW - Sibutramine

KW - Weight-loss

UR - http://www.scopus.com/inward/record.url?scp=77950544389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950544389&partnerID=8YFLogxK

U2 - 10.2165/11532940-000000000-00000

DO - 10.2165/11532940-000000000-00000

M3 - Article

C2 - 20359253

AN - SCOPUS:77950544389

VL - 14

SP - 101

EP - 106

JO - Molecular Diagnosis and Therapy

JF - Molecular Diagnosis and Therapy

SN - 1177-1062

IS - 2

ER -